Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.
BIC/FTC/TAF
HIV
antiretroviral
bictegravir
efficacy
immune reconstitution
real-life
safety
switch
tolerability
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
23 05 2023
23 05 2023
Historique:
received:
31
03
2023
revised:
11
05
2023
accepted:
14
05
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single-tablet regimen for the treatment of people living with HIV (PLWH). We aimed to assess efficacy, safety, and tolerability of BIC/FTC/TAF among PLWH, with a specific focus on people older than 55 years. We recruited an observational retrospective real-life cohort, including all PLWH who underwent a therapeutic switch to BIC/FTC/TAF, independently from the previous treatment regimen (the BICTEL cohort). Longitudinal nonparametric analyses and linear models were built. After 96 weeks of follow-up, 164 PLWH were included, with 106 older than 55. Both the intention-to-treat and the per-protocol analysis showed low rates of virologic failure, independent of the pre-switch anchor drug. At week 96, a significant increase in CD4 BIC/FTC/TAF is an effective, safe, and well-tolerated switching strategy for PLWH, especially among those older than 55.
Sections du résumé
BACKGROUND
Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single-tablet regimen for the treatment of people living with HIV (PLWH). We aimed to assess efficacy, safety, and tolerability of BIC/FTC/TAF among PLWH, with a specific focus on people older than 55 years.
METHODS
We recruited an observational retrospective real-life cohort, including all PLWH who underwent a therapeutic switch to BIC/FTC/TAF, independently from the previous treatment regimen (the BICTEL cohort). Longitudinal nonparametric analyses and linear models were built.
RESULTS
After 96 weeks of follow-up, 164 PLWH were included, with 106 older than 55. Both the intention-to-treat and the per-protocol analysis showed low rates of virologic failure, independent of the pre-switch anchor drug. At week 96, a significant increase in CD4
CONCLUSION
BIC/FTC/TAF is an effective, safe, and well-tolerated switching strategy for PLWH, especially among those older than 55.
Identifiants
pubmed: 37376522
pii: v15061222
doi: 10.3390/v15061222
pmc: PMC10302527
pii:
doi:
Substances chimiques
tenofovir alafenamide
EL9943AG5J
bictegravir
8GB79LOJ07
Anti-HIV Agents
0
emtricitabine tenofovir alafenamide
0
Emtricitabine
G70B4ETF4S
Heterocyclic Compounds, 3-Ring
0
Drug Combinations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Drugs. 2018 Apr;78(5):601-606
pubmed: 29564777
J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564
pubmed: 31430369
EClinicalMedicine. 2022 May 12;48:101412
pubmed: 35706487
J Vet Pharmacol Ther. 2004 Dec;27(6):427-39
pubmed: 15601438
AIDS Patient Care STDS. 2015 Nov;29(11):582-90
pubmed: 26505968
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Lancet HIV. 2018 Jul;5(7):e347-e356
pubmed: 29925490
BMC Geriatr. 2022 Nov 30;22(1):919
pubmed: 36447144
J Antimicrob Chemother. 2016 Apr;71(4):1031-6
pubmed: 26679246
J Virus Erad. 2020 Apr 30;6(2):70-73
pubmed: 32405424
Lancet Infect Dis. 2015 Jul;15(7):810-8
pubmed: 26070969
Drugs. 2012 Jun 18;72(9):e1-25
pubmed: 22686620
AIDS. 2022 Sep 1;36(11):1511-1520
pubmed: 35466963
AIDS. 2021 May 1;35(6):939-945
pubmed: 33635844
J Clin Med. 2021 Aug 04;10(16):
pubmed: 34441755
Diagnostics (Basel). 2021 Dec 29;12(1):
pubmed: 35054243
Infez Med. 2021 Dec 10;29(4):526-529
pubmed: 35146360
JAMA Netw Open. 2020 Jun 1;3(6):e207954
pubmed: 32539152
Open Forum Infect Dis. 2021 Jul 01;8(7):ofab316
pubmed: 34307726
HIV Med. 2023 Jan;24(1):27-36
pubmed: 35527425
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097
pubmed: 27645238
Lancet HIV. 2018 Jul;5(7):e357-e365
pubmed: 29925489